CES Unveiled in Paris to Shine Spotlight on Artificial Intelligence
26.8.2019 10:00:00 EEST | Business Wire | Press release
Consumer Technology Association (CTA)®:
|
|
|
||
|
WHAT: |
The Consumer Technology Association (CTA)® today announced that CES Unveiled in Paris will focus on emerging technology and trends around artificial intelligence (AI). More than 1,000 expected attendees will be able to view the latest AI innovations, learn about the latest tech trends and network with industry leaders. |
||
|
|
|
||
|
|
An official CES 2020 preview, CES Unveiled returns to Paris for a seventh year on Tuesday, Oct. 22 at Palais Brongniart. Attendees will experience a full day of tech that will feature more than 80 companies of all sizes, influential media, senior level executives, and prominent industry influencers from France and across Europe. |
||
|
|
|
||
|
|
Attendees will discover how AI is shaping our world, from changing enterprises to affecting ethics and policy. Industry experts and thought leaders from all over Europe will share insights on AI, enterprise solutions, mobility, Internet of Things (IoT) infrastructure, autonomous vehicles, diversity and more. |
||
|
|
|
||
|
|
|||
|
WHO: |
CTA executives Gary Shapiro, president and CEO; Karen Chupka, EVP, CES; and Steve Koenig, VP, market research, will preview what’s to come and make an exclusive CES 2020 announcement during the CES 2020 Preview and Trends in Technology conference session. |
||
|
|
|
||
|
|
The conference stage will feature industry leaders and visionaries who will share insights on emerging trends in AI. Speakers include: |
||
|
|||
|
|
The full event schedule and additional speakers can be viewed here. |
||
|
|
|
||
|
DETAILS: |
CES Unveiled in Paris will be held on Tuesday, Oct. 22, 2019 at the Palais Brongniart. Attendees and media can register for the event online. For more information about exhibiting and showcasing your products and technology, please contact us at CESUnveiled@CTA.tech. To see the full event schedule, visit CES.tech. |
About CES:
CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for over 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)®, it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights. Follow CES online at CES.tech and on social.
About Consumer Technology Association:
As North America’s largest technology trade association, CTA® is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the largest, most influential tech event on the planet. Find us at CTA.tech. Follow us @CTAtech.
UPCOMING EVENTS
-
Technology & Standards Fall Forum
September 23 – Los Angeles, CA -
CES Unveiled in Amsterdam
October 17 – Amsterdam, Netherlands -
CES Unveiled in Paris
October 22 – Paris, France -
CES 2020
January 7-10, 2020 – Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190826005100/en/
Contact information
Justin Siraj
703-907-7415
jsiraj@cta.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom